Anumana 與諾華合作開發心血管疾病檢測工具 Anumana partners with Novartis to develop AI cardiovascular disease detection tools

Updated

Anumana是 EHR 數據公司nference和 Mayo Clinic的合資企業,上周宣布已與製藥巨頭諾華公司建立戰略合作夥伴關係,以開髮用於檢測心血管疾病的AI工具。

此次合作將專注於部署AI算法,分析心電圖以發現可能導致心力衰竭的左心室功能障礙和可能導致心髒病發作和中風的動脈粥樣硬化性心血管疾病。 

兩家公司將合作夥伴關係作為一種檢測潛在致命心臟病並在嚴重並發症發生之前進行干預的方式。 

Anumana, a joint venture between EHR data company nference and the Mayo Clinic, announced last week it had entered a strategic partnership with pharma giant Novartis to develop artificial intelligence tools to detect cardiovascular diseases.

The collaboration will focus on deploying AI algorithms that analyze ECGs to find left ventricular dysfunction, which can lead to heart failure, and atherosclerotic cardiovascular disease, which can cause heart attack and stroke. 

【MORE】